Foghorn Therapeutics Inc.
FHTX
$4.88
-$0.18-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 36.75% | -3.91% | -31.30% | -30.66% | -33.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.75% | -3.91% | -31.30% | -30.66% | -33.83% |
| Cost of Revenue | -9.59% | -14.56% | -11.20% | -13.89% | -13.82% |
| Gross Profit | 24.15% | 18.29% | 0.25% | 5.92% | 4.78% |
| SG&A Expenses | -2.85% | -6.62% | -9.68% | -11.30% | -12.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.03% | -12.75% | -10.84% | -13.29% | -13.50% |
| Operating Income | 18.13% | 14.96% | 3.26% | 7.57% | 7.06% |
| Income Before Tax | 14.24% | 19.18% | 9.95% | 9.91% | 8.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.24% | 20.94% | 12.78% | 13.46% | 11.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.24% | 20.94% | 12.78% | 13.46% | 11.99% |
| EBIT | 18.13% | 14.96% | 3.26% | 7.57% | 7.06% |
| EBITDA | 18.93% | 15.53% | 3.20% | 7.51% | 6.98% |
| EPS Basic | 28.55% | 40.03% | 38.37% | 38.33% | 29.65% |
| Normalized Basic EPS | 30.71% | 36.95% | 34.64% | 37.99% | 28.57% |
| EPS Diluted | 28.55% | 40.03% | 38.37% | 38.33% | 29.65% |
| Normalized Diluted EPS | 30.71% | 36.95% | 34.64% | 37.99% | 28.57% |
| Average Basic Shares Outstanding | 14.78% | 26.60% | 40.97% | 42.36% | 30.73% |
| Average Diluted Shares Outstanding | 14.78% | 26.60% | 40.97% | 42.36% | 30.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |